DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity
Patients and models of cystic fibrosis (CF) exhibit consistent abnormalities of polyunsaturated fatty acid composition, including decreased linoleate (LA) and docosahexaenoate (DHA) and variably increased arachidonate (AA), related in part to increased expression and activity of fatty acid desaturas...
Main Authors: | Sarah W. Njoroge, Michael Laposata, Waddah Katrangi, Adam C. Seegmiller |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-02-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520407837 |
Similar Items
-
A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study
by: Kevin C. Maki, et al.
Published: (2022-03-01) -
Athletes Can Benefit from Increased Intake of EPA and DHA—Evaluating the Evidence
by: Maja Tomczyk, et al.
Published: (2023-11-01) -
Differentiating EPA from EPA/DHA in cardiovascular risk reduction
by: Peter P. Toth, et al.
Published: (2022-05-01) -
Derivation of the Omega-3 Index from EPA and DHA Analysis of Dried Blood Spots from Dogs and Cats
by: William S. Harris, et al.
Published: (2022-12-01) -
EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4
by: Julie A. Eclov, et al.
Published: (2015-12-01)